Italy’s Olon expands through Indian plant
Italian active pharmaceutical ingredient (API) supplier and contract development and manufacturing organisation (CDMO) Olon has expanded its global footprint by striking a deal to buy an API facility in Mahad, India, from Novartis. Describing the plant as “established and reputable”, Olon noted that it “provides a number of lifesaving medicines to the Indian healthcare system and patients around the world”.
You may also be interested in...
Italy’s Olon has opened its new R&D hub in Milan, shortly after announcing plans to expand a key manufacturing facility in India.
API specialist Olon has announced the expansion of its pipeline with the addition of two products: pralsetinib and trilaciclib.
With Olon investing significantly in its production capacity and technical capabilities, CEO Paolo Tubertini believes the API specialist is well-positioned to provide resilience within the European supply chain. However, the chief executive also told Generics Bulletin that this robustness needs to be valued by pricing mechanisms.